AstraZeneca (NYSE:AZN)‘s stock had its “market perform” rating restated by equities research analysts at Leerink Swann in a research note issued on Thursday, Marketbeat.com reports. They currently have a $36.00 target price on the stock, up from their prior target price of $33.00. Leerink Swann’s price target points to a potential upside of 1.58% from the stock’s previous close. Leerink Swann also issued estimates for AstraZeneca’s FY2022 earnings at $3.15 EPS.

Other analysts also recently issued research reports about the stock. JPMorgan Chase & Co. raised shares of AstraZeneca from a “neutral” rating to an “overweight” rating in a research report on Friday, December 29th. Zacks Investment Research downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Credit Suisse Group raised shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a research report on Monday, October 16th. BMO Capital Markets set a $38.00 target price on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Wednesday, January 10th. Finally, Sanford C. Bernstein reissued a “buy” rating on shares of AstraZeneca in a research report on Friday, September 22nd. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have assigned a buy rating to the stock. AstraZeneca presently has an average rating of “Hold” and a consensus target price of $34.48.

AstraZeneca (NYSE AZN) opened at $35.44 on Thursday. AstraZeneca has a one year low of $26.51 and a one year high of $35.92. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 1.09. The company has a market cap of $88,812.73, a PE ratio of 8.37, a PEG ratio of 2.59 and a beta of 0.72.

AstraZeneca (NYSE:AZN) last posted its quarterly earnings data on Thursday, November 9th. The company reported $1.12 EPS for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.55. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The company had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $6 billion. During the same quarter in the prior year, the company posted $1.32 EPS. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. sell-side analysts forecast that AstraZeneca will post 1.9 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AZN. Russell Investments Group Ltd. boosted its holdings in AstraZeneca by 198.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,856,140 shares of the company’s stock worth $62,883,000 after acquiring an additional 1,235,239 shares during the period. Sector Gamma AS purchased a new position in AstraZeneca in the 3rd quarter worth approximately $25,094,000. Janus Henderson Group PLC boosted its holdings in AstraZeneca by 5,754.0% in the 3rd quarter. Janus Henderson Group PLC now owns 726,599 shares of the company’s stock worth $24,617,000 after acquiring an additional 714,187 shares during the period. Voya Investment Management LLC boosted its holdings in AstraZeneca by 38.2% in the 2nd quarter. Voya Investment Management LLC now owns 2,395,465 shares of the company’s stock worth $81,661,000 after acquiring an additional 662,481 shares during the period. Finally, Point72 Asset Management L.P. boosted its holdings in AstraZeneca by 103.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,224,939 shares of the company’s stock worth $41,501,000 after acquiring an additional 621,831 shares during the period. Hedge funds and other institutional investors own 14.75% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “AstraZeneca (AZN) Earns “Market Perform” Rating from Leerink Swann” was published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/astrazeneca-azn-earns-market-perform-rating-from-leerink-swann/1815421.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.